Arabic Arabic English English French French German German
dark

Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines

Vifor Pharma is pleased to announce that the European Society of Cardiology included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject® and Veltassa®. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Departure of Founder and CEO Heightens Uncertainty for Galapagos

Next Post

Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

Related Posts
Total
0
Share